Loading news...
Townsquare Capital LLC reduced its holdings in shares of Masimo Corporation (NASDAQ: MASI) by 70.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,685 shares of the medical equipment provider's stock after selling 6,329 shares during the quarter. Townsquare Capital
Remote and continuous patient monitoring is moving from a niche capability to a core pillar of modern healthcare, driven by aging populations, staffing shortages, and a push toward data-driven care both inside hospitals and at home. Against this backdrop, Owlet, Inc. OWLT and Masimo Corporation MASI represent two very different ways to invest in the same secular trend.
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The consensus price target hints at a 31.1% upside potential for Masimo (MASI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Investors with an interest in Medical - Instruments stocks have likely encountered both Fresenius (FMS) and Masimo (MASI). But which of these two stocks is more attractive to value investors?
BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors.
MASI posts strong fourth-quarter and full-year 2025 preliminary results with revenue and EPS above estimates, driven by core healthcare momentum.
Masimo Corporation (MASI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended January 3, 2026. Preliminary Fourth Quarter 2025 Financial Results: • Revenue is expected to be approximately $411 million, representing approximately 12% growth on a reported basis and 11% growth on a constant currency basis(1); • Non-GAAP earnings per diluted share(2), including the impact of new tariffs, are expected to be.
Shares of Masimo Corporation (NASDAQ: MASI - Get Free Report) have earned a consensus recommendation of "Hold" from the eight brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or Masimo (MASI). But which of these two companies is the best option for those looking for undervalued stocks?
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of i.
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger.
Consumer tech news roundup covering AI investments, semiconductor tensions, EV delivery updates, Big Tech strategy shifts, and policy developments shaping global technology markets.
Mixed bag of news for Apple as Masimo tumbles in quality despite patent win, on-device AI threatens data centers, and the Tim Cook-led company scales back Vision Pro production.
Despite securing a massive $634 million legal victory against Apple Inc. (NASDAQ: AAPL), Masimo Corp. (NASDAQ: MASI) is flashing warning signals in its underlying fundamentals.
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corient Private Wealth LLC lowered its position in shares of Masimo Corporation (NASDAQ: MASI) by 5.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 330,414 shares of the medical equipment provider's stock after selling 17,624 shares during the
Shares of Masimo Corporation (NASDAQ: MASI - Get Free Report) have been assigned an average recommendation of "Hold" from the eight analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to